Skip to main content
TipRanks
Go Ultimate75% OFF

Chemomab Therapeutics (CMMB) Stock Price & Analysis

328 Followers

CMMB Stock Chart & Stats

$1.62$0.09(5.88%)
At close: 4:00 PM EST
$1$1.5$2$2.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.50 - $1.72
52-Week Range
$0.92 - $2.99
Previous Close
$1.53
Volume
N/A
Average Volume (3M)
49.79K
Market Cap
$11.74M
Enterprise Value
$6.28M
Total Cash (Recent Filing)
$6.69M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.28
Next Earnings
Mar 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces fixed financial obligations and leaves less pressure from interest or debt repayment while the company advances clinical programs. This provides greater financial flexibility than a highly indebted structure, although it does not eliminate the need for future funding.

Improving Loss And Cash Burn Trend

The improvement in annual losses and cash burn suggests some expense discipline within the research-driven business. If maintained, this trend could extend the company’s funding runway and support continued development activity, even though operations remain far from self-funding.

Merger Transaction Advancing

Effectiveness of the registration statement marks substantive progress toward the planned Scipher Medicine merger and related transaction disclosures. Completion could reshape the company’s operating and financial platform, although closing remains dependent on the stated transaction requirements.

Bears Say

Pre-revenue Business Model

The absence of revenue means Chemomab has not yet demonstrated commercial traction or an internally funded operating model. Continued dependence on clinical progress before monetization leaves profitability and future financial strength reliant on successful development and eventual market adoption.

Persistent Cash Burn

Ongoing negative operating and free cash flow indicates that the company cannot currently fund research and corporate needs from operations. Continued external financing may be necessary, exposing the business to funding availability, dilution, and execution pressure over the next several quarters.

Declining Financial Base

The decline in assets and shareholders’ equity reflects continued operating losses and cash usage, reducing the financial cushion available for clinical development. Persistent erosion could increase dependence on capital raises and create greater dilution risk if the company remains unprofitable.

Chemomab Therapeutics News

CMMB FAQ

What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $0.92 and its highest was $2.99 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $11.74M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s next earnings report is estimated for Nov 06, 2026 (not yet confirmed), which is 11 days ago.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Aug 19, 2026. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.147.
Is Chemomab Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.00.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,245,607 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 5.6%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology